ReviewFrontiers in immunology2026
Mitochondrial regulation of tumor-associated macrophage function.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-associated macrophages (TAMs) adapt to hypoxia, nutrient competition, lipid accumulation, and anticancer treatment. Mitochondria contribute to this adaptation through energy metabolism, redox signaling, mitochondrial DNA (mtDNA) sensing, and metabolite-dependent regulation of gene expression. This Review examines mitochondrial dynamics, mitophagy, proteostasis, respiratory remodeling, and lipid-droplet interactions, distinguishing direct TAM evidence from findings in other experimental systems. Tumor studies link these processes to IL-12 and IL-10 production, interferon responses, antigen presentation, and lymphocyte recruitment, with effects that vary by pathway and macrophage state. These findings do not establish a single optimal level of mitochondrial quality control. We discuss how macrophage lineage, spatial niche, and treatment exposure may influence the response to mitochondrial interventions. Therapeutic development will require causal validation in defined TAM populations, selective delivery, and measurements of immune function alongside mitochondrial changes. Evidence in human TAMs and direct studies of organelle contacts remain limited. Somatic mtDNA variation is considered separately from altered gene expression and DNA release, with lineage-tracing evidence distinguished from functional causation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.